Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Katie Holmes sports a chic designer look while enjoying a stroll around New York City'Taylor Swift must be getting sick of this': Travis Kelce is SLAMMED over 'cringe' beerMultiple glass materials discovered in Chang'eWWE star Big E reveals he may NEVER wrestle again after undergoing new neck scans, with 38Confucius Institute in Nepal lauded during 1st inaugural anniversaryMomofuku backs down from 'chile crunch' trademark warPic story of dancing couple in China's XinjiangChina launches new remote sensing satelliteInt'l scientists conduct joint experiments with China's artificial sun teamScientists develop new artificial leaf
2.5908s , 6516.625 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,International Investigation news portal